TY - JOUR AU - Md. Shaifur Rahman AU - Madhuri Haque AU - S. M. Asaduzzaman PY - 2015/12/25 Y2 - 2024/03/29 TI - Demons resurrected from Angels! What are or are not the molecular clues of the rising of the teratoma or teratocarcinoma from human amniotic stem cell? JF - Progress in Stem Cell JA - PSC VL - 2 IS - 01 SE - Research Articles DO - UR - http://cellstemcell.org/index.php/PSC/article/view/119 AB - Stem cell has great therapeutic potentials as it proliferates indefinitely, as well as gives rise to other cell type in our body. However, human pluripotent stem cell (hPSC) technology faces some obstacles associated with tumorigenicity and telomere shortening. And the risk of tumorigenicity of hPSC upon transplantation is one of the major hurdles, which must be overcome before hPSC based clinical practices. Interestingly, human amniotic stem cell (hASC) showed promising results by bypassing from the drawback. But, the important question is how hASC fully or partially escape from the progression of teratoma in severe combined immunodeficiency (SCID) mice, which remains unravel. It is decisive to comprehend the molecular mechanisms responsible for that of teratogenic and this non-teratogenic effect. Evidently, teratoma represents a critical line between stem cells, differentiation and tumorigenicis. And hASC typifies as a transitional stage between human embryonic stem cell (hESC) and adult stem cell. Hence, the study of hASC as a comparative model to reverse teratoma/teratocarcinoma formation and stem cell pluripotency to deciphering the molecular signals pathways promoting teratoma by hESC/hiPSC but not by hASC. Overall, learning the mechanisms of teratoma formation reversely by inducing in hASC could provide the knowledge that improves the tissue reconstitution potential from hESC and human induced PSC. ER -